BiotechTube

Pemigatinib + Durvalumab

Phase 2Recruiting
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Intrahepatic Cholangiocarcinoma

Conditions

Intrahepatic Cholangiocarcinoma, FGFR2 Gene Rearrangement, FGFR2 Gene Mutation

Trial Timeline

Jan 27, 2026 → Jul 1, 2027

NCT ID
NCT06728410

About Pemigatinib + Durvalumab

Pemigatinib + Durvalumab is a phase 2 stage product being developed by AstraZeneca for Intrahepatic Cholangiocarcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06728410. Target conditions include Intrahepatic Cholangiocarcinoma, FGFR2 Gene Rearrangement, FGFR2 Gene Mutation.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT06728410Phase 2Recruiting

Competing Products

20 competing products in Intrahepatic Cholangiocarcinoma

See all competitors
ProductCompanyStageHype Score
ApatinibJiangsu Hengrui MedicinePhase 2
52
Apatinib and Adebrelimab in Combination With chemotherapyJiangsu Hengrui MedicinePhase 2
52
ApatinibJiangsu Hengrui MedicinePhase 2
52
FamitinibJiangsu Hengrui MedicinePhase 2
52
Camrelizumab + ApatinibJiangsu Hengrui MedicinePhase 2
52
Durvalumab + SNDX-6352AstraZenecaPhase 2
52
Durvalumab + TremelimumabAstraZenecaPhase 2
52
Durvalumab + Gemcitabine + CisplatinAstraZenecaPhase 2
52
PemigatinibIncytePhase 2
49
A4250 (odevixibat)IpsenPhase 3
74
OdevixibatIpsenPre-clinical
20
CGT4859Cogent BiosciencesPhase 1/2
38
LUM001 (Maralixibat)Mirum PharmaceuticalsPhase 2
49
MaralixibatMirum PharmaceuticalsPhase 3
74
MaralixibatMirum PharmaceuticalsPhase 2
49
MaralixibatMirum PharmaceuticalsPhase 2
49
Volixibat + PlaceboMirum PharmaceuticalsPhase 2
49
MaralixibatMirum PharmaceuticalsPhase 3
74
Maralixibat + PlaceboMirum PharmaceuticalsPhase 3
74
HMPL-453 + RabeprazoleHUTCHMEDPhase 1
28

Other Products from AstraZeneca

QuetiapineApproved
85
Dapagliflozin 5 mg + Placebo tabletApproved
85
QuetiapineApproved
85
Ticagrelor + ClopidogrelApproved
85
DurvalumabApproved
85